熱門資訊> 正文
Lantern Pharma的Starlight Therapeutics获得FDA批准，用于第IB/2a期多形胶质母细胞瘤试验
2025-08-06 20:32
- Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression
- GBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating number of cases globally
- Lantern Pharma has previously received both FDA Orphan and Fast Track Designations in GBM
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
